Approval · Notice of Compliance 20291 · 2018

DOXEPIN: Notice of Compliance 20291

Issued January 9, 2018

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 20291
Date: January 9, 2018
Company: AA Pharma Inc.Toronto, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Labelling Only
Reason: Administrative - Transfer of Drug Identification Number (DIN)

Products in this notice

Brand	DIN	Status today
DOXEPIN	02049996	Marketed
DOXEPIN	02050005	Marketed
DOXEPIN	02050013	Marketed
DOXEPIN	02050021	Marketed
DOXEPIN	02050048	Marketed
DOXEPIN	02050056	Dormant

Medicinal ingredients

DOXEPIN HCL 10 MG per CAP
DOXEPIN HCL 25 MG per CAP
DOXEPIN HCL 50 MG per CAP
DOXEPIN HCL 75 MG per CAP
DOXEPIN HCL 100 MG per CAP
DOXEPIN HCL 150 MG per CAP